Sector News

Novartis to move UK headquarters to London

November 30, 2018
Life sciences

Novartis is moving its UK headquarters to London, in a multi-million pound investment in UK life sciences, which will be complete by January 2020.

The Swiss drugs giant said it is relocating its UK headquarters to The WestWorks building on the White City Place campus, in a bold move to join London’s latest emerging life sciences cluster.

The WestWorks is home to a number of technology and innovation companies.

The area is emerging to be London’s latest life sciences cluster and is quickly becoming home to a number of pioneering life sciences companies, as well as Imperial College London’s major new research and innovation campus.

“The nature of healthcare and medicine is changing and as we pivot towards becoming a focused medicines company, powered by digital and data, we want to be closer to our customers and partners, and become better networked in the healthcare and life science ecosystem,” said Haseeb Ahmad, Novartis UK country president.

He continued, “White City is quickly becoming one of the UK’s life sciences and technology districts, and the ethos of The WestWorks campus complements how we work to deliver on our strategy to reimagine medicine.”

Professor David Gann, VP of innovation at Imperial College also commented on the move, stating: “Novartis is a natural fit for White City’s booming life sciences ecosystem, and we hope that this move will pave the way to new collaborations and partnerships to enhance our work in this area.”

By Anna Smith

Source: Pharma Times

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.